425: VERAXA & Secarna Form AOC Alliance for Autoimmune Therapies

VERAXA Biotech and Secarna Pharmaceuticals announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates for autoimmune and inflammatory diseases.

Summary

• VERAXA Biotech and Secarna Pharmaceuticals GmbH & Co. KG have initiated a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs).
• The partnership aims to create novel targeted therapies for autoimmune and chronic immune diseases by combining both companies' technology platforms.
• AOCs are designed to deliver therapeutic oligonucleotides directly to disease-relevant cells, enhancing treatment efficacy and minimizing off-target effects.
• Secarna will utilize its proprietary, AI-empowered OligoCreator discovery and development platform to identify promising oligonucleotide candidates, including antisense oligonucleotides (ASOs) and siRNA strategies.
• VERAXA will apply its technology suite, including its click chemistry conjugation platform, to design and generate highly efficacious, uniform, and safe AOCs.
• VERAXA Biotech is a proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ: VACH), with a definitive business combination agreement signed on April 22, 2025.

Sentiment

Score: 8

Explanation: The filing announces a significant strategic collaboration between two biotech companies, leveraging advanced technologies for a promising therapeutic area. Management comments are highly positive, emphasizing the versatility of technology and potential for novel therapies. The de-SPAC transaction also indicates a positive growth trajectory for VERAXA.

Positives

• The collaboration combines the specificity of monoclonal antibodies with the functional versatility of oligonucleotides, potentially leading to highly targeted therapies.
• AOCs offer enhanced treatment efficacy and minimized off-target effects by delivering therapeutic oligonucleotides directly to disease-relevant cells.
• Secarna's OligoCreator platform is expected to greatly expedite the drug discovery process, identifying safe and efficacious therapeutic candidates rapidly.
• VERAXA's click chemistry conjugation platform is designed to generate highly efficacious, uniform, and safe AOCs.
• The alliance highlights the versatility of VERAXA's technology suite and its ability to tackle opportunities with complementary partners beyond its oncology R&D focus.
• The partnership opens up a wide range of potential therapeutic applications in immunological diseases.

Risks

• The occurrence of any event, change, or circumstances that could lead to the termination of the Business Combination Agreement with Voyager Acquisition Corp.
• The outcome of any legal proceedings that may be instituted against Voyager, VERAXA, or others following the announcement of the Business Combination.
• Inability to complete the Business Combination due to failure to obtain shareholder consents and approvals, secure financing, or satisfy other closing conditions.
• Delays in obtaining, adverse conditions contained in, or inability to obtain necessary regulatory approvals for the Business Combination.
• Changes to the proposed structure of the Business Combination required by laws, regulations, or as a condition for regulatory approval.
• Actual results may differ materially and adversely from projections, estimates, and forecasts of revenue and other financial/performance metrics.
• VERAXA's ability to scale and grow its business, source and retain talent, and maintain its cash position post-Business Combination.
• The ability to meet stock exchange listing standards in connection with, and following, the consummation of the Business Combination.
• The risk that the Business Combination disrupts current plans and operations of VERAXA.
• The ability to recognize the anticipated benefits of the Business Combination, which may be affected by competition, growth management, relationship maintenance, and employee retention.
• Costs related to the Business Combination.
• Changes in applicable laws, regulations, political, and economic developments.
• VERAXA may be adversely affected by other economic, business, and/or competitive factors.
• Failure to realize estimated shareholder redemptions, purchase price, and other adjustments.
• Additional unknown or currently immaterial risks could cause actual results to differ from forward-looking statements.

Future Outlook

The collaboration is expected to unlock novel targeted therapies for autoimmune and chronic immune diseases, leveraging the combined technological strengths of both companies. VERAXA anticipates becoming a publicly traded company listed on NASDAQ upon the closing of its business combination with Voyager Acquisition Corp. The companies aim to rapidly advance the discovery and development of next-generation antibody-based therapeutics.

Management Comments

• "Todays alliance with Secarna highlights once more the versatility of our technology suite and the range of opportunities we can tackle with partners that are complementary to our R&D focus in oncology," commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA.
• "AOCs represent a very attractive additional pocket in our industry where our expertise and antibody conjugation technology can enable unique therapeutic modalities. We are thrilled to partner with Secarna, a renowned expert in the field of developing oligonucleotide-based therapies," added Christoph Antz.
• "We are truly excited to collaborate with VERAXA on this new class of highly targeted therapeutics," said Konstantin Petropoulos, Ph.D., CEO of Secarna Pharmaceuticals.
• "The combination of our oligonucleotide platform with VERAXAs complementary ADC technologies, together with our mutual expertise in discovering and developing best-in-class therapeutics, will open up a wide range of potential therapeutic applications in the field of immunological diseases," stated Konstantin Petropoulos.

Industry Context

The collaboration between VERAXA and Secarna aligns with a growing trend in the biopharmaceutical industry towards developing highly targeted therapies, particularly for complex diseases like autoimmune and inflammatory conditions. Antibody Oligonucleotide Conjugates (AOCs) represent an innovative modality, combining the precision of antibodies with the gene-modulating power of oligonucleotides, aiming to overcome limitations of traditional treatments by reducing off-target effects and enhancing efficacy. This approach is gaining traction as companies seek to develop more effective and safer drugs for unmet medical needs.

Legal Proceedings

• Potential legal proceedings that may be instituted against Voyager, VERAXA, or others following the announcement of the Business Combination are listed as a risk factor.

Stakeholder Impact

• **Shareholders (Voyager & future VERAXA):** Potential for increased value through the development of novel therapies and the successful completion of the business combination.
• **Patients:** Potential for new, more effective, and targeted treatment options for autoimmune and chronic immune diseases.
• **Employees (VERAXA & Secarna):** Opportunities for collaboration and innovation in drug discovery and development.
• **Investment Professionals:** Provides new data points for evaluating VERAXA's strategic direction and growth potential ahead of its public listing.

Next Steps

• Further development and discovery of next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and inflammatory diseases.
• Completion of the business combination agreement between VERAXA Biotech and Voyager Acquisition Corp., leading to VERAXA becoming a publicly traded company on NASDAQ.
• Voyager and/or VERAXA intend to file relevant materials with the SEC, including a Registration Statement and proxy statement/prospectus, in connection with the Business Combination.

Key Dates

Keywords

VERAXA Biotech, Secarna Pharmaceuticals, Antibody Oligonucleotide Conjugates, AOCs, Autoimmune Diseases, Inflammatory Diseases, OligoCreator, Click Chemistry, Targeted Therapies, Oligonucleotide Therapeutics, ASOs, siRNA, Drug Discovery, Biotechnology, Strategic Collaboration, Voyager Acquisition Corp, De-SPAC, Business Combination